Related Experiment Video
Updated: May 26, 2026

Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
Surgical treatment of metabolic syndrome
Sharon Williams1, Emily Cunningham, Walter J Pories
1Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
Abstract:
This article explores the surprising finding that bariatric surgery can produce full and durable remission of the metabolic syndrome as well as other comorbidities of obesity including type II diabetes, hypertension, polycystic ovary syndrome, gastroesophageal reflux disease, nonalcoholic steatotic hepatitis, adult asthma and improvement in weight-bearing arthropathy. Such an outcome was previously deemed impossible. One effect of the surgery is the correction of hyperinsulinemia, a common denominator in the various expressions of the metabolic syndrome. Basal insulin levels return to normal levels within a matter of days following surgery, allowing a return of the first phase of insulin secretion. This effect is 'dose related' to the extent of the reduction of contact between food and the gut. The resolution of the spectrum of diseases that comprise the metabolic syndrome following bariatric surgery suggests that hyperinsulinemia may be the common cause that is corrected by lowering contact between food and the gut. If this concept is true, then the cause of the syndrome, including diabetes, could be a diabetogenic signal from the gut that forces the islets to produce excessive and harmful levels of insulin, or the cause could be the removal of a signal that blocks excessive insulin secretion. If either of these mechanisms is proven correct, the current treatment of diabetes with long-term insulin administration deserves review.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Atherosclerosis III: Management
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Oral Hypoglycemic Agents: Biguanides and Glitazones
Mitral Stenosis III: Medical Management
Cardiomyopathy V: Interprofessional Care

